In vivo and in vivo, paeonol administration not only prevented cisplatin‐induced HC loss and inner HC synaptic degeneration but also conferred protection against noise‐induced HC damage and hearing loss, demonstrating broad otoprotective efficacy.
Abstract
ABSTRACT Background Hearing loss primarily results from irreversible cochlear hair cell (HC) damage caused by factors such as noise, aging, genetics, and ototoxic drugs including cisplatin. Currently, there are no effective clinical otoprotective agents available. The natural compound paeonol, derived from Paeonia suffruticosa, exhibits potential anti‐inflammatory and antioxidant properties, positioning it as a promising therapeutic candidate given the central roles of oxidative stress and inflammation in hearing loss pathogenesis. Methods and Results Using mouse cochlear explant cultures, we demonstrated that paeonol protects against cisplatin‐induced HC damage in a concentration‐dependent manner and reduces the accumulation of MitoSOX, TNF‐α, and IL‐6. In vivo, paeonol administration not only prevented cisplatin‐induced HC loss and inner HC synaptic degeneration but also conferred protection against noise‐induced HC damage and hearing loss, demonstrating broad otoprotective efficacy. Mechanistically, RNA‐seq analysis revealed that paeonol exerts its protective effect partly by preventing ribosome biogenesis dysfunction, thereby ensuring normal protein synthesis in HCs. Conclusions Together, our work demonstrates the efficacy of paeonol across multiple models and reveals a potential protective mechanism, paving the way for its development as a much‐needed otoprotective drug.
Cisplatin is a potent, broad-spectrum chemotherapeutic agent widely used against multiple malignancies, yet its clinical utility is substantially restricted by dose-limiting adverse effects dominated by nephrotoxicity and ototoxicity. Although cisplatin-induced ototoxicity has been recognized for decades, the precise...
Zhen-Xian Zhang, Ya-Qiong Zhu, Feng-Xu Yan et al.· Cell Death Discovery· 0 citations
Background Cisplatin is a widely used chemotherapeutic agent, but its clinical application is limited by serious ototoxic side effects, including hearing loss, tinnitus, and vertigo. Inflammation is now recognized as a significant contributor to cisplatin-induced hearing loss, but the upstream regulators remain largely...
Weilong Wang, Shengyu Zou, Danqi Wang et al.· Military Medical Research· 0 citations
Cisplatin-induced hearing loss (CIHL) affects half a million cancer patients annually, but treatment strategies are limited. We have previously shown that honokiol, an antioxidant and otoprotective compound, upregulates mitochondrial sirtuin 3 (SIRT3) and protects against CIHL. In the present study, we investigated the...
Chail Koo, Robert J Fuentes, Prerita Pandya et al.· Biomedicine & pharmacotherap...· 0 citations
Noise-induced permanent hearing loss results primarily from the irreversible loss of cochlear sensory hair cells, which do not regenerate in adult mammals. Endoplasmic reticulum (ER) stress may play a major role in noise-induced outer hair cell (OHC) loss. We previously reported that FK506 prevents noise-induced hearin...
Hong-Guo Su, Fan Wu, K. Haque et al.· Hearing Research· 0 citations
Cisplatin‐induced ototoxicity is a common adverse effect of cisplatin‐based chemotherapy and significantly impairs the quality of life in cancer patients. Mechanistically, the STAT6 signaling pathway is critically involved in regulating the generation of pro‐inflammatory cytokines, which contributes to cisplatin‐indu...
Irreversible cisplatin-induced hearing loss (CIHL) is a refractory chemotherapy-related adverse effect with limited clinical treatments. Schisantherin B (STB), a lignan isolated from Schisandra chinensis, is widely recognized for its neuroprotective properties, while its role in auditory injury remains unclear. Herein,...
Zi-Wen Gao, Hui Huang, Ping Yang et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.